Helicobacter pylori(H. pylori) infection is associated with various gastric and extra‐gastric diseases. Importantly, this infection is the strongest known risk factor for gastric cancer (GC).H. pylorieradication can effectively preventH. pyloriinfection‐associated diseases inH. pylori‐positive patients, including children and elderly subjects. However, a limited selection of antibiotics, a higher reinfection rate, and certain spontaneous clearance rates, to some extent, restrict the choice ofH. pyloritreatments in pediatrics. In addition, it is imperative to perform an accurate diagnosis ofH. pyloriinfection in children by determining the presence of theH. pyloriinfection and the underlying cause of symptoms. In elderly patients, poor tolerance to drugs and higher sensitivity to adverse effects are major concerns duringH. pyloritherapy. Recent studies have demonstrated thatH. pylorieradication could significantly lower the GC risk in the elderly population. The benefit and risk ofH. pylorieradication in elderly patients should be comprehensively considered and balanced. If available, susceptibility‐based tailored therapies may be preferable in eradicatingH. pylori. In addition, to increase the eradication rate and reduce adverse effects, new therapeutic strategies (e.g., probiotic supplementation, berberine supplementation, dual therapy) forH. pyloriinfection are being extensively investigated. The impact ofH. pylorieradication with antibiotics on the microbiota in children has been explored, but further high‐quality studies are crucial to delineate the extent ofH. pylorieradication affecting the microbial community in children. In this review, we summarize the current understanding ofH. pyloridiagnosis and treatment in children and the elderly population and aim to provide insights into the efficient management and treatment implementation in these populations.